In: Crohn's disease17 Aug 2012
Thalidomide has been shown to have antitumour necrosis factor (anti-TNF) properties and has been reported to be effective in two open-label studies dealing with Crohn’s disease . The first report of this phenomenon appeared in the Lancet in 1997 in a paper by Wettstein and Meagher . They reported the case of a 32-year-old woman who had had multiple small bowel and colonic resections for complicated Crohn’s disease resulting in short bowel syndrome. The patient was treated with all of the current medications at the time, including total parenteral nutrition, metronidazole and cyclosporine, without success.
The patient was then treated with 300 mg of thalidomide per day, and the report stated that aside from sleepiness, no other side effects were noted. The patient was maintained on 100 mg of thalidomide daily up until the time of the report with resolution of the disease.
The following case report further expands the clinical experience with this drug, and other case reports regarding the efficacy of this drug in the disease are summarized.
Find out more about your chance to get Zyrtec tablets at best online pharmacy.
Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.